

## PRODUCT INFORMATION

<b>Clone ID</b>	DMC369
<b>Target</b>	Her2
<b>Synonyms</b>	ERBB2;CD340;HER-2:neu;HER2;MLN19;NEU;NGL;TKR1
<b>Host Species</b>	Rabbit
<b>Description</b>	PE-conjugated Anti-HER2 antibody(DMC369); IgG1 Chimeric mAb
<b>Delivery</b>	Under Development
<b>Uniprot ID</b>	P04626
<b>IgG type</b>	Rabbit/Human Fc chimeric IgG1
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	Human
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Liquid□PBS with 0.05% Proclin300, 1% BSA
<b>Storage &amp; Shipping</b>	Store at 2°C-8°C for 6 months

**Background**

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However; it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer; stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways; such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported; with the most common allele; Ile654:Ile655; shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers; including breast and ovarian tumors. Alternative splicing results in several additional transcript variants; some encoding different isoforms and others that have not been fully characterized.

**Usage** Research use only

**Conjugate** PE-conjugated

**DIMA Disclaimer** All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

